Our findings indicated that NFE2L1 is predominantly expressed in glioma tumor tissues, with NFE2L2 exhibiting lower expression levels, whereas NFE2L3 was expressed at minimal levels (Figure 1A). The gene discussed is NFE2L3; the disease is central nervous system cancer.